

GÃ¼nther Hochhaus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5939881/publications.pdf>

Version: 2024-02-01

147
papers

4,160
citations

109321

35
h-index

144013

57
g-index

154
all docs

154
docs citations

154
times ranked

3370
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers. AAPS Journal, 2022, 24, 9.	4.4	0
2	iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. Molecular Pharmaceutics, 2022, 19, 2032-2039.	4.6	13
3	iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes. Molecular Pharmaceutics, 2022, 19, 2040-2047.	4.6	12
4	Dissolution and drug release. , 2021, , 225-266.		2
5	Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?. AAPS Journal, 2021, 23, 48.	4.4	13
6	Semi-mechanistic PK/PD model to assess pulmonary targeting of beclomethasone dipropionate and its active metabolite. European Journal of Pharmaceutical Sciences, 2021, 159, 105699.	4.0	3
7	Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches. Pharmaceutics, 2021, 13, 1109.	4.5	6
8	Evaluation of the Sensitivity and Robustness of Modified Chi-Square Ratio Statistic for Cascade Impactor Equivalence Testing Through Monte Carlo Simulations. AAPS PharmSciTech, 2020, 21, 147.	3.3	0
9	Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales. Journal of Clinical Pharmacology, 2020, 60, 1051-1060.	2.0	8
10	Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 235-238.	1.4	27
11	Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies. AAPS Journal, 2020, 22, 39.	4.4	4
12	Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products. Dissolution Technologies, 2020, 27, 52-70.	0.6	2
13	Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach. AAPS PharmSciTech, 2019, 20, 249.	3.3	5
14	Fetal Concentrations of Budesonide and Fluticasone Propionate: a Study in Mice. AAPS Journal, 2019, 21, 53.	4.4	4
15	Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY(3-36) after pulmonary delivery. Drug Development and Industrial Pharmacy, 2019, 45, 1101-1110.	2.0	1
16	Characterization of a dextran-budesonide prodrug for inhalation therapy. European Journal of Pharmaceutical Sciences, 2019, 129, 58-67.	4.0	13
17	Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling. , 2019, , 79-120.		9
18	Effects of lipid formulations on clove extract spray dried powders: comparison of physicochemical properties, storage stability and in vitro intestinal permeation. Pharmaceutical Development and Technology, 2018, 23, 1047-1056.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2017, 34, 2541-2556.	3.5	36
20	Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. <i>AAPS Open</i> , 2016, 2, .	1.3	73
21	Cholestenolic acid, an endogenous cholesterol metabolite, is a potent Î³-secretase modulator. <i>Molecular Neurodegeneration</i> , 2015, 10, 29.	10.8	16
22	Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant. <i>Molecular Pharmaceutics</i> , 2015, 12, 2618-2624.	4.6	58
23	A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach. <i>AAPS Journal</i> , 2015, 17, 999-1010.	4.4	13
24	Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 391-399.	1.8	5
25	Application of the Modified Chi-Square Ratio Statistic in a Stepwise Procedure for Cascade Impactor Equivalence Testing. <i>AAPS Journal</i> , 2015, 17, 370-379.	4.4	7
26	Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuousâ€rate infusion in the horse. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 133-144.	1.3	2
27	Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 678-686.	3.2	20
28	Pharmacometrics in Pulmonary Diseases. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 349-382.	0.6	2
29	Development of a placebo effect model combined with a dropout model for bipolar disorder. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 359-368.	1.8	13
30	Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. <i>Therapeutic Delivery</i> , 2013, 4, 343-367.	2.2	39
31	A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution. <i>AAPS Journal</i> , 2013, 15, 1-9.	4.4	17
32	A Pharmacokinetic Simulation Tool for Inhaled Corticosteroids. <i>AAPS Journal</i> , 2013, 15, 159-171.	4.4	53
33	A Sensitivity Analysis of the Modified Chi-square Ratio Statistic for Equivalence Testing of Aerodynamic Particle Size Distribution. <i>AAPS Journal</i> , 2013, 15, 465-476.	4.4	12
34	Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. <i>Planta Medica</i> , 2013, 79, 312-312.	1.3	0
35	Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Flunisolide in Tissue Culture Medium. <i>Analytical Letters</i> , 2013, 46, 1355-1363.	1.8	0
36	Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats. <i>Planta Medica</i> , 2012, 78, 1831-1836.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Equivalence Considerations for Orally Inhaled Products for Local Actionâ€”ISAM/IPAC-RS European Workshop Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 117-139.	1.4	54
38	Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 79-89.	4.0	8
39	Systemic exposure to fluticasone MDI delivered through antistatic chambers. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1113-1115.e3.	2.9	8
40	Brain permeability of inhaled corticosteroids. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 1159-1167.	2.4	17
41	Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristicsâ€”. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 1473-1484.	2.4	3
42	Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. <i>Brain Research Bulletin</i> , 2010, 81, 320-326.	3.0	10
43	Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 1-29.	1.4	93
44	Budesonide and Ciclesonide: Effect of Tissue Binding on Pulmonary Receptor Binding. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1421-1426.	3.3	16
45	Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R1445-R1454.	1.8	38
46	Slow Release Formulations of Inhaled Rifampin. <i>AAPS Journal</i> , 2008, 10, 342-348.	4.4	70
47	Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance. <i>Respiratory Research</i> , 2008, 9, 75.	3.6	6
48	Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: Potential effects on clinical safety and efficacy. <i>Clinical Therapeutics</i> , 2008, 30, 1-13.	2.5	54
49	Pharmacokinetics and Pharmacodynamics of Inhaled Glucocorticoids. <i>Journal of Asthma</i> , 2008, 45, 13-24.	1.7	16
50	Simultaneous Determination of Dexamethasone, Dexamethasone 21â€”Acetate, and Paclitaxel in a Simulated Biological Matrix by RPâ€”HPLC: Assay Development and Validation. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2008, 31, 1478-1491.	1.0	9
51	Evaluation of the Administration Time Effect on the Cumulative Cortisol Suppression and Cumulative Lymphocytes Suppression for Onceâ€”Daily Inhaled Corticosteroids: A Population Modeling/Simulation Approach. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1069-1080.	2.0	15
52	Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor. , 2008, 49, 5094.		18
53	Fluticasone furoate nasal spray in allergic rhinitis. <i>Drugs of Today</i> , 2008, 44, 251.	1.1	1
54	Advances in single-entity inhaled corticosteroid therapy. <i>Allergy and Asthma Proceedings</i> , 2007, 28, 125-135.	2.2	3

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 98, S7-S15.	1.0	10
56	Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 439-444.	2.4	29
57	Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 698-705.	2.4	17
58	Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. <i>Journal of Drug Targeting</i> , 2006, 14, 680-686.	4.4	11
59	Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. <i>Journal of Pediatrics</i> , 2006, 149, 793-797.	1.8	16
60	Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 412-419.	2.4	50
61	Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 441-459.	1.8	14
62	Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. <i>European Respiratory Journal</i> , 2006, 27, 511-516.	6.7	35
63	METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 225-233.	3.3	23
64	CONTRARY TO ADULT, NEONATAL RATS SHOW PRONOUNCED BRAIN UPTAKE OF CORTICOSTEROIDS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 939-942.	3.3	20
65	A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 175-179.	2.3	15
66	Budesonide in previously untreated autoimmune hepatitis. <i>Liver International</i> , 2005, 25, 927-934.	3.9	86
67	Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 519-532.	5.0	41
68	Comparative Pharmacology, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Inhaled Glucocorticosteroids. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 469-488.	1.9	94
69	New Developments in Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 269-274.	3.5	39
70	In Vitro and in Vivo Anti-Inflammatory Activity of the New Glucocorticoid Ciclesonide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 249-258.	2.5	102
71	How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 356-363.	3.5	98
72	In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered-Dose Inhaler. <i>Pharmacotherapy</i> , 2004, 24, 159-166.	2.6	11

#	ARTICLE	IF	CITATIONS
73	Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. <i>AAPS Journal</i> , 2004, 6, 68-73.	4.4	17
74	Identification of Stabilized Dynorphin Derivatives for Suppressing Tolerance in Morphine-Dependent Rats. <i>Pharmaceutical Research</i> , 2004, 21, 1450-1456.	3.5	7
75	Pharmacokinetic aspects of biotechnology products. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2184-2204.	3.3	268
76	Simultaneous quantification of beclomethasone dipropionate and its metabolite, beclomethasone 17-monopropionate in rat and human plasma and different rat tissues by liquid chromatography- ⁺ positive electrospray ionization tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 203-210.	2.3	9
77	A Novel Method for Polymer Coating of Plasmid DNA: Initial Investigations into the Use of Pulse Laser Deposition and Gene Delivery. <i>Journal of Drug Targeting</i> , 2004, 12, 237-241.	4.4	1
78	Intranasal Lofeprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 510-519.	2.0	8
79	Drugs used in the treatment of opioid tolerance and physical dependence: a review. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 42, 191-203.	0.6	54
80	In Vitro Performance of Two Common Valved Holding Chambers with a Chlorofluorocarbon-Free Beclomethasone Metered-Dose Inhaler. <i>Pharmacotherapy</i> , 2003, 23, 1538-1544.	2.6	12
81	SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma. <i>Biomedical Chromatography</i> , 2003, 17, 14-20.	1.7	10
82	Simultaneous quantification of budesonide and its two metabolites, 6 β -hydroxybudesonide and 16 β -hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2003, 17, 158-164.	1.7	23
83	Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determination of plasma protein binding and verification of percent labeled claim of various creatine products. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 794, 157-165.	2.3	20
84	Pharmacokinetics of the Dietary Supplement Creatine. <i>Clinical Pharmacokinetics</i> , 2003, 42, 557-574.	3.5	93
85	Single- and Multiple-Dose Pharmacokinetics of Oral Creatine. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 29-37.	2.0	39
86	Performance of a Corticosteroid Inhaler with a Spacer Fashioned from a Plastic Cold-Drink Bottle: Effects of Changing Bottle Volume. <i>Journal of Asthma</i> , 2003, 40, 237-242.	1.7	5
87	Population Pharmacokinetics and Pharmacodynamics of Ciclesonide. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 365-378.	2.0	96
88	Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. <i>Current Medical Research and Opinion</i> , 2003, 19, 491-499.	1.9	177
89	In Vitro Comparison of Fluticasone Respirable Dose From a Metered-Dose Inhaler and Three Ridged Valved Holding Chamber. <i>Chest</i> , 2003, 124, 137S.	0.8	0
90	A New Solution-Based Intranasal Triamcinolone Acetonide Formulation in Patients with Perennial Allergic Rhinitis: How Does the Pharmacokinetic/Pharmacodynamic Profile for Cortisol Suppression Compare with an Aqueous Suspension-Based Formulation?. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 662-669.	2.0	7

#	ARTICLE	IF	CITATIONS
91	In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 88, 204-208.	1.0	12
92	Differences in Inhaled Fluticasone Bioavailability Between Holding Chambers in Children with Asthma. <i>Pharmacotherapy</i> , 2002, 22, 947-953.	2.6	13
93	Pharmacokinetics of plasmid DNA in the rat. <i>Pharmaceutical Research</i> , 2001, 18, 67-74.	3.5	33
94	Receptor binding studies of soft anticholinergic agents. <i>AAPS PharmSci</i> , 2001, 3, 44-56.	1.3	36
95	Methods used to assess pulmonary deposition and absorption of drugs. <i>Drug Discovery Today</i> , 2001, 6, 367-375.	6.4	58
96	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate after Single and Multiple Administration in Healthy Subjects and Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 536-541.	2.0	13
97	Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). <i>Journal of Clinical Pharmacology</i> , 2001, 41, 425-434.	2.0	39
98	Single-Dose and Steady-State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry-Powder Inhalers to Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1329-1338.	2.0	34
99	Pharmacokinetic Considerations in the Design of Pulmonary Drug Delivery Systems for Glucocorticoids. <i>Drugs and the Pharmaceutical Sciences</i> , 2001, , .	0.1	2
100	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	2.0	20
101	A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 123-129.	2.8	36
102	An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. <i>AAPS PharmSci</i> , 2000, 2, 28-37.	1.3	15
103	Analysis of leucine enkephalin by high-performance liquid chromatography using enzymatic derivatization by tyrosinase and electrochemical or fluorescence detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1999, 19, 855-864.	2.8	9
104	Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: The metabolism of dynorphin A(1-13) and related fragments in human plasma. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 938-944.	3.3	6
105	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 127-147.	0.6	17
106	Kinetic modeling of plasmid DNA degradation in rat plasma. <i>AAPS PharmSci</i> , 1999, 1, 15-20.	1.3	53
107	Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 27-38.	4.7	16
108	Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. <i>Pharmaceutical Research</i> , 1998, 15, 461-465.	3.5	34

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. <i>European Journal of Clinical Pharmacology</i> , 1998, 53, 459-467.	1.9	65
110	A selective HPLC/RIA for the determination of budesonide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 1235-1242.	2.8	12
111	Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 704-710.	2.0	30
112	Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 881-892.	2.0	96
113	Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 893-903.	2.0	24
114	Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 916-925.	2.0	55
115	An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 101-109.	2.8	6
116	Pulmonary targeting of liposomal triamcinolone acetonide phosphate. <i>Pharmaceutical Research</i> , 1996, 13, 1699-1703.	3.5	32
117	Metabolism of dynorphin A1-13 in human CSF. <i>Neurochemical Research</i> , 1996, 21, 1213-1219.	3.3	11
118	Metabolism of dynorphin A 1-13 in human blood and plasma. <i>Pharmaceutical Research</i> , 1995, 12, 1165-1170.	3.5	29
119	Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. <i>Pharmaceutical Research</i> , 1995, 12, 134-137.	3.5	29
120	Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. <i>Pharmaceutical Research</i> , 1995, 12, 1096-1100.	3.5	48
121	Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 302-305.	2.0	100
122	Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1187-1193.	2.0	51
123	Response to the Commentary on "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs". <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1067-1068.	3.3	1
124	Leucine enkephalin-tyrosinase reaction products - Identification and biological activity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1222, 95-100.	4.1	5
125	P149 new electrochemical and fluoregenic assays for leucine enkephalin based on enzymatic derivatization by tyrosinase. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 156.	4.0	0
126	P140 a selective HPLC/RIA assay for budesonide in biological fluids. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 153.	4.0	0

#	ARTICLE	IF	CITATIONS
127	P225 metabolism of DYN a 1â€“13 in human plasma. European Journal of Pharmaceutical Sciences, 1994, 2, 175.	4.0	0
128	Clinical Pharmacology of Pancreatic Enzymes in Patients with Cystic Fibrosis and <i>In Vitro</i> Performance of Microencapsulated Formulations. Journal of Clinical Pharmacology, 1994, 34, 158-166.	2.0	59
129	PK/PD analysis of albuterol action: application to a comparative assessment of Î²2-adrenergic drugs. European Journal of Pharmaceutical Sciences, 1993, 1, 73-80.	4.0	0
130	Receptorâ€“Based Pharmacokineticâ€“Pharmacodynamic Analysis of Corticosteroids. Journal of Clinical Pharmacology, 1993, 33, 115-123.	2.0	120
131	Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharmaceutical Research, 1992, 09, 291-297.	3.5	26
132	A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomedical Chromatography, 1992, 6, 283-286.	1.7	8
133	Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs. Journal of Pharmaceutical Sciences, 1992, 81, 1210-1215.	3.3	38
134	cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Molecular and Cellular Endocrinology, 1991, 78, 155-162.	3.2	15
135	Soft drugsâ€”10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 149-154.	2.5	93
136	A new fluorogenic assay for tyrosine-containing peptides. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 557-563.	2.8	3
137	A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 761-767.	2.8	10
138	Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharmaceutical Research, 1990, 07, 558-560.	3.5	3
139	Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents and Actions, 1990, 30, 377-380.	0.7	15
140	An avidinâ€”biotin based enzyme-linked immunosorbent assay for dynorphin A 1â€“13. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 541-545.	2.8	0
141	[Biocytin-13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor. Pharmaceutical Research, 1988, 05, 790-794.	3.5	5
142	A biotin-avidin-based enzyme immunoassay for beta h-endorphin. Pharmaceutical Research, 1988, 05, 232-235.	3.5	4
143	Delta opioid receptor in human neuroblastoma cell lines. Brain Research, 1986, 382, 327-331.	2.2	23
144	HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 1986, 4, 197-206.	2.8	50

#	ARTICLE	IF	CITATIONS
145	Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents and Actions, 1986, 17, 290-291.	0.7	26
146	Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. Journal of Pharmaceutical and Biomedical Analysis, 1985, 3, 566-573.	2.8	12
147	Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Research in Experimental Medicine, 1983, 182, 71-78.	0.7	13